Indication
Sleep-onset insomnia
Sleep-onset insomnia, also known as initial insomnia, is a sleep disorder characterized by difficulty initiating sleep at bedtime despite adequate opportunity and circumstances for rest. Read more about Sleep-onset insomnia
72 drugs 54 manufacturers
Drugs that treat it
Common Sleep-onset insomnia therapies.
RAMELTEON
ZALEPLON
ZOLPIDEM TARTRATE
RAMELTEON
ZOLPIDEM TARTRATE
ZOLPIDEM TARTRATE
RAMELTEON
ZALEPLON
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSleep-onset insomnia, also known as initial insomnia, is a sleep disorder characterized by difficulty initiating sleep at bedtime despite adequate opportunity and circumstances for rest.
It involves central nervous system dysregulation and can affect individuals of any age group, though it is particularly prevalent in adolescents and young adults.
Clinically, it is defined by prolonged sleep-onset latency—commonly exceeding 30 minutes—which frequently leads to daytime fatigue, cognitive impairment, mood disturbances, and reduced functional capacity.
Pathophysiologically, the condition is driven by cognitive, somatic, and neuroendocrine hyperarousal, characterized by elevated sympathetic nervous system tone, increased evening cortisol secretion, and heightened metabolic activity that impede the transition into non-rapid eye movement sleep.
- nih.gov
Sleep-onset insomnia, also known as initial insomnia, is a sleep disorder characterized by difficulty initiating sleep at bedtime despite adequate opportunity and circumstances for rest Clinically, it is defined by prolonged sleep-onset latency—commonly exceeding 30 minutes—which frequently leads to daytime fatigue, cognitive impairment, mood disturbances, and reduced functional capacity
- upenn.edu
Sleep-onset insomnia, also known as initial insomnia, is a sleep disorder characterized by difficulty initiating sleep at bedtime despite adequate opportunity and circumstances for rest
- nih.gov
It involves central nervous system dysregulation and can affect individuals of any age group, though it is particularly prevalent in adolescents and young adults
- harvard.edu
It involves central nervous system dysregulation and can affect individuals of any age group, though it is particularly prevalent in adolescents and young adults
- nih.gov
Clinically, it is defined by prolonged sleep-onset latency—commonly exceeding 30 minutes—which frequently leads to daytime fatigue, cognitive impairment, mood disturbances, and reduced functional capacity
- nih.gov
Pathophysiologically, the condition is driven by cognitive, somatic, and neuroendocrine hyperarousal, characterized by elevated sympathetic nervous system tone, increased evening cortisol secretion, and heightened metabolic activity that impede the transition into non-rapid eye movement sleep
- nih.gov
Pathophysiologically, the condition is driven by cognitive, somatic, and neuroendocrine hyperarousal, characterized by elevated sympathetic nervous system tone, increased evening cortisol secretion, and heightened metabolic activity that impede the transition into non-rapid eye movement sleep
- nih.gov
Pathophysiologically, the condition is driven by cognitive, somatic, and neuroendocrine hyperarousal, characterized by elevated sympathetic nervous system tone, increased evening cortisol secretion, and heightened metabolic activity that impede the transition into non-rapid eye movement sleep
Personalize your experience
Follow Sleep-onset insomnia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.